<DOC>
	<DOCNO>NCT00583830</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( disease response ) safety mapatumumab combination carboplatin paclitaxel first line therapy subject advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Mapatumumab Combination With Paclitaxel Carboplatin Subjects With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients histologically cytologically confirm stage IIIB stage IV advance primary nonsmall cell lung cancinoma Age 18 year old Received investigational ( yet approve regulatory authority ) noninvestigational agent treat Lung Cancer Received radiation therapy within 4 week randomization Major surgery within 4 week randomization Minor surgery within 2 week randomizaiton Systemic steroid within 1 week randomization Any grade 2 great neuropathy History severe ( Grade 4 ) hypersensitivity reaction product contain Cremophor EL ( cyclosporine , teniposide ) History infection require hospitalization antibiotic within 2 week randomization Known brain spinal cord metastases History cancer within 5 year randomization Known HIV , hepatitisB hepatitisC infection Pregnant breastfeed woman Previously treat Mapatumumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Lung Cancer</keyword>
</DOC>